Medpace Holdings, Inc.
MEDP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.61 | 1.55 | 0.57 | 1.76 |
| FCF Yield | 5.56% | 4.21% | 5.10% | 3.01% |
| EV / EBITDA | 20.51 | 25.65 | 23.39 | 34.02 |
| Quality | ||||
| ROIC | 37.24% | 38.78% | 40.36% | 16.23% |
| Gross Margin | 31.12% | 27.81% | 29.62% | 28.73% |
| Cash Conversion Ratio | 1.51 | 1.53 | 1.58 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.04% | 18.19% | 16.39% | 9.89% |
| Free Cash Flow Growth | 44.25% | 12.97% | 49.40% | 3.40% |
| Safety | ||||
| Net Debt / EBITDA | -1.09 | -0.28 | 0.53 | -1.50 |
| Interest Coverage | 0.00 | 690.22 | 95.94 | 1,891.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 43.13 | 49.21 | 51.60 | 48.06 |